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Abstract: Craniofacial bone defect anomalies affect both soft and hard tissues and can be caused by
trauma, bone recessions from tumors and cysts, or even from congenital disorders. On this note,
cleft/lip palate is the most prevalent congenital craniofacial defect caused by disturbed embryonic
development of soft and hard tissues around the oral cavity and face area, resulting in most cases,
of severe limitations with chewing, swallowing, and talking as well as problems of insufficient
space for teeth, proper breathing, and self-esteem problems as a consequence of facial appearance.
Spectacular advances in regenerative medicine have arrived, giving new hope to patients that can
benefit from new tissue engineering therapies based on the supportive action of 3D biomaterials
together with the synergic action of osteo-inductive molecules and recruited stem cells that can be
driven to the process of bone regeneration. However, few studies have focused on the application
of tissue engineering to the regeneration of the cleft/lip and only a few have reported significant
advances to offer real clinical solutions. This review provides an updated and deep analysis of the
studies that have reported on the use of advanced biomaterials and cell therapies for the regeneration
of cleft lip and palate regeneration.
Keywords: cleft palate; cleft lip; regenerative medicine; bone; craniofacial defects; orofacial disorders;
musculoskeletal tissue engineering
1. Introduction
Craniofacial defects generally cause significant negative impacts on the quality of life and
self-esteem of those individuals with musculoskeletal dysfunctionalities. Cleft lip, with or without
cleft palate (CL/P), is the most prevalent congenital craniofacial defect caused by disturbed embryonic
development of soft and hard tissues around the oral cavity and face area [1]. Current treatments for
this orofacial condition generally demand early surgery and face reconstruction procedures that may
be revised during childhood and infancy, causing a great number of patient complaints and economic
burden to health systems that need to be minimized. Due to these reasons, alveolar cleft reconstruction
has been considered one of the most controversial surgical procedures and less invasive therapies
have being demanded since the beginning of the 20th century [2]. Fortunately, tissue engineering is
rapidly providing successful regenerative therapies to several musculoskeletal conditions based on the
synergic triad of using functional biomaterials, in conjunction with the vehiculization and local delivery
of bioactive regenerative molecules and guided or recruited stem cells (Figure 1) that can modulate
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the etiopathogenesis of the disease and its prevalence by promoting the missing self-repairment
mechanisms of affected tissues, thus improving the life conditions of affected patients. The functional
reconstruction of highly vascularized bones, such as the craniofacial area, is a key challenge in bone
tissue engineering, since it depends fundamentally on a well-organized hierarchical vascular network.
The cell survival and viability, as well as the elimination of metabolic waste are in charge of the supply of
oxygen and nutrients carried out by the blood vessels, in this way, the restoration of the neovasculature
contributes to improve bone functionality [3]. Scaffold materials should allow vascular regeneration in
a fundamental way as well as provide structure, osteonduction and osteoconduction characteristics
when applied in the field of craniofacial regeneration [4]. Thus, accordantly with different authors,
an ideal bone construction should combine a weightbearing rigid scaffold design, a porous structure
that mimics the bone architecture, and cell-laden materials that favor new vascular formation [5].
The pore size and shape of a particular biomaterial play a key role in vascular ingrowth [6]. However,
the size of the interconnections seems to be more important for the vascularization of a scaffold when
compared with the pore size [7]. As such, fabrication designs, biocompatibility characteristics, porosity
and matrix density are of critical consideration [3]. Despite the importance of this knowledge in the
study of the craniofacial defect regeneration, there have been few studies on CL/P that deepen in assays
on the neovascularization of tissues through the proposal of new materials. This review provides an
updated and deep analysis of the studies that have reported on the use of advanced biomaterials and
cell therapies for the regeneration of cleft lip and palate regeneration.
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changes in shape and growth as the brain expands simultaneously for the formation of the branchial 
arches responsible for the development of the face and the cranium. Alar structures of the nose are 
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pieces of the tissue engineering puzzle for cleft/lip palate regeneration.
1.1. Etiopathogenesis of Orofacial Cleft
Cleft palate (CL/P) malformation occurs as a result of the non-fusion of the primary palate
during the fourth and 12th weeks of gestation [2,8]. During this period, the embryo undergoes rapid
changes in shape and growth as the brain expands simultaneously for the formation of the branchial
arches responsible for the development of the face and the cranium. Alar structures of the nose are
formed by the lateral nasal process while, during the mandibular processes that take place during
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the eighth week, the shelves ascend above the tongue and then fuse, forming the secondary palate
completing the formation of the jaw, the upper lip, alveolus, and primary palate [2]. Like any other
structural formation in the human body, the entire process is guided by a precise synchronization
and balance of cell adhesion, proliferation, and differentiation, regulated by cell signaling molecules
from which the family of transforming growth factor beta (TGF-b), fibroblast growth factors (FGFs),
bone morphogenic proteins (BMPs), and sonic hedgehog (SHH) [2,9] stands out. Dysfunctions on
these pathways, mediated by gene regulation, are responsible for most of the common presentations of
human maxillary alveolar cleft, a bony oronasal communication lined by epithelialized mucosa and
partially erupted or unerupted teeth within the cleft [10].
Environmental factors or maternal metabolic imbalances and infections during embryogenesis
ultimately contribute to the etiology of musculoskeletal dysfunctionalities being maternal folic acid
deficiency during the periconceptional period or exposure to alcohol and teratogenic medications,
i.e., retinoids, corticosteroids, and the anticonvulsant phenytoin and valproic acid, which is the main
cause of cleft disorders [2].
1.2. Prevalence
Orofacial cleft conditions have been estimated to have a global annual prevalence of 7.94 cases per
10,000 live births with high variances of treated patients across regions and countries (Figure 2) [11].
In some European countries, for example, the prevalence of CL/P has been reported between 0.53 to
1.59 cases per 1000 live births [12], while the countries that have reported the highest and lowest rates
were Japan (19.05) and South Africa (3.13), respectively. On the other hand, in the American continent,
the overall case rate is 10.49 per 10,000 live births and this figure is surpassed by some countries
in South America (i.e., Bolivia with 23.7, Ecuador with 14.96, and Paraguay with 13.3). Conversely,
the lowest figures were presented in countries such as Venezuela with 7.92, Peru with 8.94, Uruguay
with 9.37, and Brazil with 10.12, all for 10,000 live births [13]. Within the USA, the average prevalence
of cleft lip with or without cleft palate was 7.75 per 10,000 live births, showing differences between
ethnicities [14].
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1.3. Cost at the Health, Social and Economic Level
CL/P is considered as an anatomical defect of profound aesthetic and functional impact that
leads to other future alterations, and therefore may negatively impact health-related quality of life,
and/or speech [12]. Individuals with clefts of the lip, palate, or alveolus often require interdisciplinary
treatment into adulthood and thus they require timely and effective care. In addition, the repercussions
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of this disease affect the family nucleus and the social environment that in many cases may carry the
financial burden of extensive treatment, and a variety of psychosocial challenges [13,15]. The economic
impact of CL/P therapies on national health systems is difficult to estimate due to the number of
analyses and examinations that every child born with a CL/P must go through for several years.
Routine analysis of airway obstruction, in relation to feeding capacity and nutritional intake, weight
and growth rates, different musculoskeletal abnormalities, genetic tests to associate syndromes and
craniofacial examination to evaluate the shape of the head, ears, eyes, nose, jaws and oral cavity need
to be assessed, costing up to $2.4 billion per year according to the World Health Organization [16].
2. Clinical Demands
The management of patients with CL/P pathology is complex and requires a multidisciplinary
approach that includes plastic surgeons, maxillofacial surgeons (cleft surgeons), otolaryngologists,
speech/language pathologists, audiologists, dentists, orthodontists, psychologists, geneticists, and social
workers. Different tissues including bone, dental organs, and soft tissue from the respiratory system
are largely affected during the CL/P reconstruction (Figure 3), therefore it is necessary to standardize
the perioperative management of these patients [17].
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the ultimate facial appearance of the child. To achieve this goal, the most common palatoplasty 
techniques currently accepted are the von Langenbeck technique, the Bardach 2-flap palatoplasty, 
the Veau–Wardill–Kilner closure, the 2-stage palatoplasty, and the Furlow palatoplasty [1]. 
Ultimately, there is also variability on the optimal timing to perform palate repair. As transverse 
facial growth is not completed until five years of age, some surgeons have considered retarding cleft 
palate repair, even to as late as age 8 or 10, to reduce the risk of midface hypoplasia, while others 
may consider an earlier repair before the age of two, in order to improve speech development and 
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some malformation around the orofacial area responsible for causing respiratory and speech/language
problems. Deformation of the arch and dental crowding (A), crossbite dental malposition (B), and the
deviated nasal septum (C) as revealed by panoramic radiographs showing the maxillary defect (circle)
(unpublished data).
Regarding the reconstruction of alveolar cleft defects, the most accepted approach consists of the
secondary alveolar cleft osteoplasty in the mixed dentition phase [10]. The goal of this surgery is to
achieve a normal facial appearance as well as the ability to feed, speak, and hear without affecting
the ultimate facial appearance of the child. To achieve this goal, the most common palatoplasty
techniques currently accepted are the von Langenbeck technique, the Bardach 2-flap palatoplasty,
the Veau–Wardill–Kilner closure, the 2-stage palatoplasty, and the Furlow palatoplasty [1]. Ultimately,
there is also variability on the optimal timing to perform palate repair. As transverse facial growth
is not completed until five years of age, some surgeons have considered retarding cleft palate repair,
even to as late as age 8 or 10, to reduce the risk of midface hypoplasia, while others may consider
an earlier repair before the age of two, in order to improve speech development and achieve better
integration in society with less psychosocial impact for the children and families. Taking the middle
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position, some surgeons have managed cleft palate repair in two stages, with soft palate repair at three
to six months and hard palate repair at 15 to 18 months, while others have advocated a single-stage
repair with both the soft and hard palates being repaired simultaneously. Unfortunately, none of
these surgeries are definitive and may present long-term complications including palatal fistula,
velopharyngeal insufficiency, and midface hypoplasia resulting in facial growth disturbance in multiple
dimensions and cross bite abnormalities such as transverse maxillary hypoplasia that need to be
managed by orthodontic maxillary expansion with fixed appliances and supported by bone grafting in
order to consolidate the dental arch and teeth alignment [1,18].
Nowadays, the use of autogenous bone is the most widely used type of grafting in bone
regeneration defects [2,19]. However, the availability of autogenous bone is limited and is not free of
tremendous drawbacks, especially in pediatric patients where the availability for harvesting bone may
be limited and thus may not be the ideal graft for alveolar bone reconstruction. In itself, this process is
usually invasive and has the potential for significant morbidities to occur at the donor site, such as
infection, paresthesia, postoperative pain and scarring problems [19,20]. As an alternative, tissue
engineering strategies offer the possibility of using artificial custom made supports for tissues and
cells with the aim for them to be applied in the affected area to promote the regeneration of missing or
damaged tissues.
The current bioartificial tissues designed for cleft palate reconstruction have been mostly based
on inserted granules isolated with a single tissue layer [10,21]. However, the alveolar cleft defect
typically consists of a two-wall bony defect in which mucoperiosteal flaps are sutured in two layers
to create a new nasal floor and a continuous oral mucosa. As a consequence, the free motion of the
inserted granules negatively affects the dimensional stability and biomechanical properties of the
reconstructed sites, difficulty with the correct closure of these mucoperiosteal flaps, and isolation
from microorganisms that can infect the graft [22]. In order to overcome these limitations, the most
sophisticated approaches to CL/P repair consider the fabrication of biomodels with a 3D shape and
microstructure similar to patients’ bone defects to test the biomechanical properties of bone substitutes
and evaluate the clinical effects with respect to osteogenesis and healing, first in vitro and second in
experimental animals. Several animal models have been utilized for the testing of alveolar cleft grafting
materials including mice, rabbits, cats, dogs, goats, sheep, and monkeys, with rats being the most
referred model among them due to their ease of handling and cost effectiveness. However, these defects
made on rats are significantly smaller in volume than human alveolar defects, thus it is difficult to
extrapolate the results [8,23]. In order to overcome these limitations, according to Pourebrahim et al.,
artificial biomodels created in experimental animals had to fulfill the following criteria: there had to be
a bilateral maxillary alveolar cleft with a 15 mm bony width in each research animal, with demonstrable
oronasal communication, covered by healthy epithelialized mucosa; and there must be functional teeth
on each side [10].
Some authors have also evaluated in vivo genetically induced CL/P models in rats. It was
described that due to a sevoflurane-induced gene deletion, an incomplete development of the palate
and alveolus was achieved. However, in many cases, the gene defect led to other pathologies and
perinatal lethality, therefore, this methodology has been considered as not suitable to evaluate new
bone grafts [17,24].
Stem Cells Alternative and Growth Factor Assisted Regeneration
Adult stem cells are considered fundamental for cell therapy because of their unique ability to
self-renew and differentiate into various phenotypes, in addition to being obtained from different
tissues and have been used for craniofacial defect regeneration in tissue engineering. Adipocyte stem
cells (ADSCs) are particularly desirable candidates for musculoskeletal tissue engineering applications
such as cleft lip and palate [10]. In this sense, Pourebrahin et al. proposed the use of adipose tissue
in maxillary alveolar cleft defects, due to their potential for differentiation, the easy accessibility to
this source of cells, and their capability to rapidly expand in vitro. The authors studied the potential
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of ADSCs seeded in biphasic bone substitutes of hydroxyapatite/calcium triphosphate (HA/TCP) to
repair maxillofacial bone defects (Figure 4) in a dog model, concluding that they were an acceptable
alternative for the reconstruction of human maxillofacial bone defects in the case of limited autograft
availability or morbidity in the donor site [10].
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3. Biomaterials for Soft and Hard Cleft Tissue Repair
Biomaterials play a key role in the tissue engineering strategy for the restoration of missing
tissue and its functionality. In particular, the advances in bone regeneration using biomimetic 3D
scaffolds made of bioceramics, polymers, and composites, using different manufacturing methods
(i.e., 3D printing, cryopolymerization, synthesis, etc.), have permitted the exploration of new options
for the repair of tissues in CL/P treatment.
3.1. Bioceramics
Bioceramics such as hydroxyapatite (HA),α-tricalciumphosphates (αTCP) andβ-tricalciumphosphates
(βTCP), demineralized bone matrices, calcium carbonates, calcium sulfates, bioactive glasses, and composite
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materials in combination with bioactive inorganic materials (bioglasses, etc.) constitute an important
group of biomaterials used to manufacture adequate scaffolds in relation to novel treatments
for CL/P due to their desired biological properties in terms of osteoconduction, biocompatibility,
chemical similarity with natural bone and facilitate proliferation and osteoblast differentiation [30,31].
Janssen et al. described osteoinductive microstructured βTCP granules, embedded in a glycerol matrix,
as an alternative to autologous bone grafts for alveolar cleft repair because of their ability to induce bone
formation when implanted at heterotopic sites in a bilateral alveolar goat cleft model. These authors
hypothesized that the quality of residual bone and the volume of the putty would work at least equal
to the autograft and, even, the surgical management would be superior to the use of the regular
β-TCP granules (Figure 5) [22]. Contrary to these findings, Korn et al. showed that when using
hydroxyapatite/collagen composite scaffolds, the ossification of the defect was not enhanced, probably
due to the micromovements of the remaining non-resorbable HA particles after their degradation of
the collagen that hampered, as in the case of autografts, the ossification of the defects. Nevertheless,
most of the investigations using scaffolds based on bioceramics are supported by cell therapy and
growth factors and although the osteoinduction mechanism has not yet been completely revealed,
the relationship between the physical and chemical features of the osteoinductive bioceramic and
the osteogenic differentiation of HMSCs and their suitability for craniofacial defect repair including
alveolar cleft palate regeneration has been demonstrated [8,17,19,21,25].
Int. J. Mol. Sci. 2019, 20, x 7 of 13 
 
(bioglasses, etc.) constitute an important group of biomaterials used to manufacture adequate 
scaffolds in relation to novel treatments for CL/P due to their desired biological properties in terms 
of osteoconduction, biocompatibility, chemical similarity with natural bone and facilitate 
proliferation and osteoblast differentiation [30,31]. Janssen et al. described osteoinductive 
microstructured βTCP granules, embedded in a glycerol matrix, as an alternative to autologous bone 
grafts for alveolar cleft repair because of their ability to induce bone formation when implanted at 
heterotopic sites in a bilateral alveolar goat cleft model. These authors hypothesize  that the quality 
of residual bone and the volume of the putty would w rk at least qual to the autog aft and, even, 
the surgical management would be superior to the use of the regular β-TCP granule  (Figure 5) [22]. 
Contrary to these findings, Korn et al. showed that when u ing hydroxyapatite/collagen composite 
scaffolds, the ossification of the defect wa  not enhanced, probably due to the micromovements of 
the remaining non-r sorbable HA particles after their degradation of the collagen that hampered, as 
in the case of autografts, the ossification of the defects. Nev rtheless, most of the investigations using 
scaff lds based on bioceramics are supported by cell therapy and growth factors and alt ough the 
osteoinduction mechanism has not yet been co pletely revealed, the relationshi  between the 
physical and chemical features of the osteoinductive bioceramic and the osteogenic differentiation of 
HMSCs and their suitability for craniofacial defect repair including alveolar cleft palate regeneration 
has been demonstrated [8,17,19,21,25]. 
 
Figure 5. (Left) Induced bone formation by beta-TCP in the maxillary cleft of goats (A). Material 
(stars) is reabsorbed by a multinucleated osteoclast-like cell (arrowhead) (B). Elsewhere, cuboidal 
osteoblasts (black arrow heads) lay down new bone (pink) adjacent to an osteocyte (white arrow) in 
its lacuna. Reproduced from Janssen et al. (2017) [22] with permission from SAGE Publications ®. 
Scale bars: 250 μm (left), 25 μm (right A, B).  
3.2. Polymeric Biomaterials 
Recent advances in macromolecular sciences and tissue engineering methods have made it 
possible to efficiently generate several human artificial tissues including the oral mucosa and 
maxillofacial bone such as cleft palate [32]. Several synthetic polymer scaffold materials have been 
used for these purposes including poly (ε-caprolactone) (PCL), poly(lactic acid) (PLA), poly(glycerol 
sebacate) (PGS), poly (lactide-co-glycolide) (PLGA), or polyhydroxyalkanoates (PHA), among others 
[33]. These polymers can be synthesized in large quantities under controlled conditions, thus ensuring 
uniform and reproducible properties while reducing the risks of infections and immunogenicity [34]. 
For example, Flores-Cedillo et al. prepared membrane composites made of multiwall carbon 
nanotubes (MWCNTs) with PCL, demonstrating their ability to allow adhesion and proliferation of 
human dental pulp stem cells (HDPSCs) (Figure 6), and promoting their osteogenic differentiation 
toward bone like phenotypes permitting bone regeneration, and thus suitable for CL/P regeneration. 
Figure 5. (Left) Induced bone formation by beta-TCP in the maxillary cleft of goats (A). Material (stars)
is reabsorbed by a multinucleated osteoclast-like cell (arrowhead) (B). Elsewhere, cuboidal osteoblasts
(black arrow heads) lay down new bone (pink) adjacent to an osteocyte (white arrow) in its lacuna.
Reproduced from Janssen et al. (2017) [22] with permission from SAGE Publications ®. Scale bars:
250 µm (left), 25 µm (right A, B).
3.2. Polymeric Biomaterials
Recent advances in macromolecular sciences and tissue engineering methods have made it possible
to efficiently generate several human artificial tissues including the oral mucosa and maxillofacial
bone such as cleft palate [32]. Several synthetic polymer scaffold materials have been used for
these purposes including poly (ε-caprolactone) (PCL), poly(lactic acid) (PLA), poly(glycerol sebacate)
(PGS), poly (lactide-co-glycolide) (PLGA), or polyhydroxyalkanoates (PHA), among others [33].
These polymers can be synthesized in large quantities under controlled conditions, thus ensuring
uniform and reproducible properties while reducing the risks of infections and immunogenicity [34].
For example, Flores-Cedillo et al. prepared membrane composites made of multiwall carbon nanotubes
(MWCNTs) with PCL, demonstrating their ability to allow adhesion and proliferation of human dental
pulp stem cells (HDPSCs) (Figure 6), and promoting their osteogenic differentiation toward bone like
phenotypes permitting bone regeneration, and thus suitable for CL/P regeneration.
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to sup ort bone-forming cells and within cleft palate bone defects [36]. Moreover, th se scaffolds
can be evelope by incorporating hybrid natural erived biomaterials such as collagen or chitosan,
t a in combination with PCL and PLGA copolymer nan fibers serve to offer scaffolding options with
superior os eogenic potential by combining the bio imetic and stimulating effects of natural polymers
and the structu al and mechanical stability apabilities of s nthetic polymers [37–41]. On this note,
an alternative strategy p opos d by Zaky et al. aimed to enhance biocompatibility, i degradability,
and material elasticity by cr ating a biomimetic c llular niche based on poly glycerol se cate (PGS) in
which bone m rrow stromal cells were mechanically stimulated to produce their own extracellular
matrix leading to a biochemically mimicking environment of bone, while enabling the transmission of
mechanical forces wi h the objective of treati g craniofacial malformations including CL/P [42].
4. New Manufacturing Techniques for Cleft Palate Reconstruction
Some of the most challenging difficulties for craniofacial defect regeneration are derived from the
variety of tissue-specific requirements and the complexity of anatomical structures in that region [43,44].
Thus, hierarchical micro-structured and custom-made scaffolds are often required for regenerative
therapies. Fortunately, the current advances in the fabrication of in situ click-chemistry based injectable
formulations, controlled cryopolymerization methods, electrospinning, and 3D direct printing of
complex structures with composite biomaterials are able to provide scaffolds with adequate nano-,
micro- and macro-structure and composition for CL/P repair. On this note, Hixon et al. described
cryogel scaffolds as tissue-engineered constructs formed at sub-zero temperatures, with excellent
potential for the treatment of patient-specific bone defects (Figure 7). In addition, these authors used
patient-specific 3D-printed molds derived from computed tomography for scaffold fabrication during
the thawing of the cryogels, resulting in a macroporous, sponge-like, and mechanically durable product
for the creation of site-specific implants in the treatment of patients with CL/P [45].
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Maternal folic acid during the periconceptional period is considered to be one of the main 
causes of clefting disorders. A recent review published by Fernandez Villa et al. [46] highlighted the 
potential of folic acid as a key bioactive compound to enhance the effectiveness of biomaterial 
performance and biological functions for the regeneration of tissues and organs. In addition, new 
derivatives of folic acid bearing bioactive cations such as Sr or Zn have been proven to be promising 
compounds with the ability to accelerate bone formation in craniofacial defects [47] and reduce 
inflammation [48]. 
The therapy based on Sr seems promising due to its proven action in improving preosteoblast 
replication, osteoblast differentiation, synthesis of collagen type I, and mineralization of the bone 
matrix. Nonetheless, any formulation should provide an effective and consistent way to deliver Sr2+ 
ions with low or the absence of secondary pharmacological effects. In this regard, Rojo et al. 
developed a carrier for Sr based on folic acid with a remarkable capacity of enhancing bone tissue 
formation and synergic benefits on cell replication and differentiation processes. In agreement with 
these authors, Martín-del-Campo et al. demonstrated that the incorporation of strontium folate 
within 3D porous bio-hybrid scaffolds provided an excellent system for the regeneration of bone 
tissue into the craniofacial area (Figure 8) [39]. The use of these strontium folate derivatives, in 
combination with HDPSC and biomimetic scaffolds, is a promising alternative that can be used at 
accessible cost for bone regeneration, in particular during CL/P treatment. 
Figure 7. Analysis of a patient custom made patient cryogel. (a) SEM images taken at 1000 and 200X
(left to right). (b) mCT 3D reconstruction images representing both the scaffold (grey) and the inner
pores with the color bar denoting the size of the pores within the cryogel (left to right). Reproduced
from Hixon et al. (2017) [45] with permission from SAGE®.
5. Folic Acid Derivatives as Osteoinductive Molecules for Cleft Palate Regeneration
Maternal folic acid during the periconceptional period is considered to be one of the main causes
of clefting disorders. A recent review published by Fernandez Villa et al. [46] highlighted the potential
of folic acid as a key bioactive compound to enhance the effectiveness of biomaterial performanc and
bi logic l functions for the regeneration of tissues a orga s. In addition, new derivatives of fol c
acid beari g bioactive cations s ch as Sr or Zn have been proven to be promisin compoun s with the
ability o accelerate bone formation in craniofacial defect [47] and reduce inflammation [48].
The therapy bas d on Sr seems promising due to its proven ction in improving preosteoblast
rep ication, osteoblast differentiation, synthesis of collagen type I, and mineralization of the bone
matrix. Nonetheless, any fo mulation should provide an effective and consistent way t deliver
Sr2+ ions with low or the absence f secondary pharm cological effects. In this regard, Rojo et al.
developed a carri r for Sr based on folic aci with a remarkable c pacity of enhancing bone tissue
formation and synergic benefits on c ll replication and differentiation processe . In agreement with
th se authors, Martín-del-Campo et al. demonstrated that the incorporation of strontium folate w thin
3D porous bio-h brid s affolds provided an excellent system for the regeneration of bon tissue into
the craniofacial area (Figure 8) [39]. The use of the e strontium folate de ivatives, in combination with
HDPSC and biomimetic scaffolds, is a promising alter ativ that can be used at acc ssible cost f r bone
regen rati n, in particular during CL/P treatment.
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4, 12, and 20 weeks, and defect closure on the side of the implants form the coronal plane (arrows) 
and 3D images (circles) and bone density of the radiographic density (HU) in cranial defects. (* = 
Significant differences p < 0.001). Reproduced from [39] with permission from the Royal society for 
Chemistry. 
6. Conclusions and Future Perspectives 
The success of synthetic bone grafts is based on their capacity to promote osteoconductivity and 
osteoinductivity during the formation of new bone growth. In addition, the use of low molecular 
weight compounds such as those derived from folic acid and bioactive cations constitutes a 
promising alternative to the use of protein-based growth factors and morphogens, for the 
preparation of resorbable scaffolds in the maxillary defect model to allow osteoconduction and 
osteoinduction in the defects. In this regard, the use of bioceramics such as calcium phosphate in 
combination with biomimetic polymer scaffolds, folic acid derivatives, morphogens, and stem cells 
are currently considered as the most promising alternative for CL/P regeneration. In addition, 
emerging bioprinting technologies in combination with advanced manufacturing techniques such 
electrospinning or cryogelation processes have permitted the development of new tissue substitutes 
with a precise control of sizes and shapes to recreate the complex physiological, biomechanical, and 
hierarchical microstructure of biological tissues that are necessary for the regeneration of 
malformations such as CL/P. 
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Figure 8. icro-computed tomography images of cranial defects treated with TCP/SrFO scaffolds at 4,
12, and 20 weeks, and defect closure on the side of the implants form the coronal plane (arrows) and 3D
images (circles) and bone density of the radiographic density (HU) in cranial defects. (* = Significant
differences p < 0.001). Reproduced from [39] with permission from the Royal society for Chemistry.
6. Conclusions and Future Perspectives
The uccess of synthetic bon graft is based on their capacity to promote osteoconductivity and
osteoinductivity during the formation of new bone growth. In addition, the use of low molecular
weight compounds such as those derived from folic acid and bioactive cations constitutes a promising
alternative to the use of protein-based growth factors and morphogens, for the preparation of resorbable
scaffolds in the maxillary defect model to allow osteoconduction and osteoinduction in the defects.
In this regard, the use of bioceramics such as calcium phosphate in combination with biomimetic
polymer scaffolds, folic acid derivatives, morphogens, and stem cells are currently considered as the
most promising alternative for CL/P regeneration. In addition, emerging bioprinting technologies in
combination with advanced manufacturing techniques such electrospinning or cryogelation processes
have permitted the development of new tissue substitutes with a precise control of sizes and shapes
to recreate the complex physiological, biomechanical, and hierarchical microstructure of biological
tissues that are necessary for the regeneration of malformations such as CL/P.
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